The National Health Surveillance Agency (Anvisa) received a request from the Butantan Institute to include the age group from 3 to 5 years in the indication of the Coronavac vaccine.
The evaluation period for this new order is up to seven working days and starts counting from Monday (14).
“The technical analysis will be carried out by Anvisa in a rigorous way and with all the necessary caution for this specific audience”, informed the Agency, after receiving the request on the night of this Friday (11).
If the request is granted by Anvisa, Coronavac may be the first vaccine against the coronavirus authorized for children from 3 years of age.
Currently, pediatric immunization against covid-19 is allowed from the age of 5, but only the Pfizer vaccine is authorized for children of that age. From the age of 6, they can receive Pfizer or Coronavac.
